WORLD HEALTH ORGANIZATION

WHO approves MVA-BN vaccine as first mpox vaccine for prequalification, aiming to facilitate timely access and reduce transmission. The vaccine, administered in 2 doses 4 weeks apart, can be stored at 2–8°C for up to 8 weeks and is recommended for high-risk individuals, including 'off-label' use in children and pregnant women. Single-dose use is advised in supply-constrained situations, with estimated 76% effectiveness pre-exposure and 82% with 2 doses.

Bavarian Nordic’s MVA-BN vaccine is the first mpox vaccine to receive WHO pre-qualification, enabling global use. WHO recommends single doses in supply-constrained situations and 'off label' use for children and immuno-compromised individuals. The vaccine is currently approved for adults, with ongoing studies for younger age groups. Bavarian Nordic aims to produce two million doses by the end of 2024.

WHO authorized an mpox vaccine, crucial for combating outbreaks in Africa, particularly in the Democratic Republic of the Congo. The vaccine, produced by Bavarian Nordic, is limited to a single manufacturer and primarily authorized for adults. Wealthy countries have already approved it, and donations are planned, but Africa CDC estimates 10 million vaccines are needed. Mpox, milder than smallpox, causes fever, chills, and body aches, with severe cases developing lesions.

WHO announced MVA-BN vaccine as the first mpox vaccine to be added to its prequalification list, facilitating increased access to reduce transmission. The vaccine, administered in two doses four weeks apart to those over 18, can be stored at 2-8°C for up to eight weeks. This prequalification aims to accelerate procurement and rollout, ensuring equitable access and saving lives.

WHO approves MVA-BN as the first mpox vaccine on its pre-qualification list, effective at 82% with two doses. The vaccine is recommended for those over 18, with potential off-label use in younger and vulnerable groups. WHO aims to accelerate global access to the vaccine amid ongoing outbreaks.

WHO prequalifies MVA-BN vaccine for mpox, facilitating access to reduce transmission. Recommended for high-risk individuals, it can be used off-label in children, pregnant women, and immunocompromised people. Single-dose use is advised in supply-constrained situations. WHO emphasizes data collection on safety and effectiveness, with ongoing assessments for other mpox vaccines.

Consumer Reports found elevated lead levels in 1/3 of 36 tested cinnamon products, with some reaching 3.5 ppm, prompting warnings to discard items with 1 ppm or more. The Codex Alimentarius is considering a 2.5 ppm limit for lead in bark spices, including cinnamon.

WHO announced MVA-BN vaccine as the first mpox vaccine on its prequalification list, aiming to facilitate timely access and reduce transmission. The vaccine, administered in two doses four weeks apart, can be stored at 2-8°C for up to eight weeks. WHO Director-General Tedros Adhanom Ghebreyesus emphasized the need for urgent scale-up in procurement and rollout for equitable access.

Bavarian Nordic's IMVANEX® (MVA-BN®) becomes the first mpox vaccine to receive WHO prequalification, facilitating broader access across African countries. The vaccine, indicated for adults, may be used 'off-label' in vulnerable groups during outbreaks. MVA-BN has also received provisional consent from New Zealand and full approval from Mexico.

GSK reports positive interim Phase II trial results for its mRNA-based multivalent influenza vaccine candidate, GSK4382276A, meeting pre-defined success criteria in both younger and older adult groups. The vaccine, encoding antigens matched to WHO-recommended influenza strains, showed potential for improved immune responses compared to current vaccines, prompting GSK to advance the programme into late-stage clinical development.